Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Announces Earnings Results, Beats Estimates By $0.06 EPS

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) released its earnings results on Tuesday. The company reported $0.27 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.21 by $0.06, FiscalAI reports. The firm had revenue of $214.27 million during the quarter, compared to analyst estimates of $207.12 million. Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.

Kiniksa Pharmaceuticals International Stock Performance

KNSA opened at $43.61 on Tuesday. The business's 50-day simple moving average is $45.94 and its 200-day simple moving average is $42.86. Kiniksa Pharmaceuticals International has a one year low of $21.25 and a one year high of $50.03. The stock has a market capitalization of $3.34 billion, a P/E ratio of 58.93 and a beta of 0.06.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other news, CEO Sanj K. Patel sold 7,278 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $50.01, for a total transaction of $363,972.78. Following the sale, the chief executive officer owned 7,278 shares in the company, valued at approximately $363,972.78. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry D. Quart sold 6,901 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $50.00, for a total value of $345,050.00. Following the sale, the director owned 12,546 shares in the company, valued at $627,300. This trade represents a 35.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 61,479 shares of company stock valued at $2,832,812. 53.48% of the stock is owned by insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

A number of hedge funds and other institutional investors have recently made changes to their positions in KNSA. Qube Research & Technologies Ltd grew its holdings in shares of Kiniksa Pharmaceuticals International by 277.8% during the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company's stock worth $24,581,000 after buying an additional 653,236 shares during the last quarter. Rubric Capital Management LP grew its holdings in shares of Kiniksa Pharmaceuticals International by 15.6% during the second quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company's stock worth $108,184,000 after buying an additional 526,567 shares during the last quarter. Cubist Systematic Strategies LLC grew its holdings in shares of Kiniksa Pharmaceuticals International by 213.2% during the second quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company's stock worth $18,192,000 after buying an additional 447,536 shares during the last quarter. Nomura Holdings Inc. purchased a new position in shares of Kiniksa Pharmaceuticals International during the third quarter worth about $15,421,000. Finally, Logos Global Management LP purchased a new position in shares of Kiniksa Pharmaceuticals International during the fourth quarter worth about $14,438,000. Hedge funds and other institutional investors own 53.95% of the company's stock.

Wall Street Analyst Weigh In

KNSA has been the subject of a number of recent analyst reports. Wedbush lifted their price target on Kiniksa Pharmaceuticals International from $53.00 to $58.00 and gave the stock an "outperform" rating in a report on Thursday, April 16th. Canaccord Genuity Group initiated coverage on Kiniksa Pharmaceuticals International in a report on Thursday, February 19th. They set a "buy" rating and a $62.00 price target for the company. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a "buy" rating to a "hold" rating in a report on Sunday. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Kiniksa Pharmaceuticals International in a report on Tuesday, April 21st. Finally, Zacks Research downgraded Kiniksa Pharmaceuticals International from a "hold" rating to a "strong sell" rating in a report on Friday, April 17th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $56.00.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company's core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company's lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease and Schnitzler syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.